

ATC codes: **L02BA01**

Indication	Other specified malignant neoplasms of breast	ICD11 code: 2D1Y
INN	Tamoxifen	
Medicine type	Chemical agent	
List type	Complementary	
Formulations	Oral > Solid: 10 mg (as citrate) ; 20 mg (as citrate)	
EML status history	First added in 1984 (TRS 722) Changed in 2002 (TRS 914) Changed in 2015 (TRS 994)	
Sex	All	
Age	Adolescents and adults	
Therapeutic alternatives	The recommendation is for this specific medicine	
Patent information	Patents have expired in most jurisdictions Read more about patents . 	

Tags

Cancer

Wikipedia

[Tamoxifen](#) 

DrugBank

[Tamoxifen](#) 

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for tamoxifen on the complementary list of the EML for use in treatment protocols for hormone-receptor positive metastatic breast cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for metastatic breast cancer is attached.

[Expert Committee report](#) 

